Yarrow Bioscience

YARW

Biotechnology · Healthcare

Price

$36.42

-1.77 (-4.65%)

Market Cap

$626,364

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Dividends

Weak

Track this stock — start free trial

Share count rising — dilution

+1395.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1K (2021) → 17K (2025)

Winston Score History

The full picture

Yarrow Bioscience Inc is a small biotechnology company focused on developing experimental drugs and therapies. Biotech companies like this one work on discovering new medicines, typically targeting diseases where current treatments are limited or unavailable. The company operates in the healthcare sector, where it is working to move drug candidates through clinical research and testing stages.

Yarrow Bioscience does not yet generate meaningful revenue from product sales, which is common for early-stage biotech firms. Its near-100% gross margin on minimal revenue and deeply negative operating margin reflect a business that spends heavily on research and development while relying on capital raises — such as stock offerings or partnerships — to fund operations. The company's main risk is straightforward: it must successfully advance its drug pipeline through clinical trials and regulatory approval before it runs out of funding, and failure at any stage could significantly threaten the business.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+40.6% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+98.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$19M/ year

↓ Declining (-38% vs prior year)

>1,000% of revenue

187.5x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Cash Runway

~3 years

$23M cash & investments

$23M cash & investments at current burn rate

Revenue accelerating

Yarrow Bioscience grew revenue 41% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-3197.9%

Losing money on operations — -3197.9%

Return on the money invested

ROCE

-90.3%

Weak — -90.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+1.3%

Nearly flat sales (+1.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-3513.1%

Burning cash (-3513.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.46%

Small dividend — 1.46% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial